

GAMMACAN INTERNATIONAL INC  
Form 8-K  
March 12, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**March 6, 2008**  
(Date of Earliest Event Reported)

**GAMMACAN INTERNATIONAL, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-32835**  
(Commission  
File Number)

**33-0956433**  
(IRS Employer  
Identification No.)

**39 Jerusalem St.**  
**Kiryat Ono 55423 Israel**  
(Address of principal executive offices)

**(972) (3) 738-2616** (Registrant's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 8.01 Other Events**

On March 6, 2008, a press release was issued by the Registrant disclosing the results of a series of significant animal experiments confirming the effectiveness of IgG preparations derived from vitiligo donors against melanoma cells. Vitiligo-derived IgG preparations are the basis for the Registrant's lead product candidate, VitiGam.

A copy of the Registrant's press release is attached as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibits.

99.1. Press Release, dated March 6, 2008.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 12, 2008

**GAMMACAN INTERNATIONAL, INC.**

By: /s/ Patrick Schnegelsberg

Name: Patrick N.J. Schnegelsberg

Title: Chief Executive Officer

---